“Progressive myoclonic ataxia and developmental/epileptic encephalopathy associated with a novel homozygous mutation in TCN 2 gene”
Molecular Genetics & Genomic Medicine · 2024
DOI: 10.1002/mgg3.2282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Mohammed Ahmed Mohammed Oshi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Division, Gaafar Ibnauf Children's Emergency Hospital, Khartoum, Sudan. Hauptthemen laut MEDLINE: Cerebellar Ataxia, Epilepsy, Epilepsy, Generalized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transcobalamin II ( TCN 2) defect is a rare metabolic disorder associated with a range of neurological manifestations, including mild developmental delay, severe intellectual disability, ataxia, and, in some cases, seizures. Cobalamin, an essential nutrient, plays a crucial role in central nervous system myelination. Clinical Presentation We present a family with an index patient who exhibited progressive neurodevelopmental regression starting at 9 months of age, accompanied by myoclonic seizures, ataxia, and tremor. No significant hematological abnormalities were observed. Exome sequencing analysis identified a novel homozygous mutation, c.3G>A – P(Met1I), affecting the acceptor site of intron 4 of the TCN 2 gene (chromosome 22: 31003321, NM_000355.4), leading to likely pathogenic variant potentially affecting translation. Following treatment with hydroxocobalamin, the patient demonstrated partial clinical improvement. He has a sibling with overt hematological abnormalities and subtle neurological abnormalities who is homozygous to the same mutation. Both parents are heterozygous for the same mutation.
Conclusions
In infants presenting with unexplained non‐specific neurological symptoms, irrespective of classical signs of vitamin B12 deficiency, evaluation for TCN 2 defect should be considered. Early diagnosis and appropriate management can lead to favorable outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Division, Gaafar Ibnauf Children's Emergency Hospital, Khartoum, Sudan.
- Department of Child Health, College of Medicine, University of Bisha, Bisha, Saudi Arabia.
- Department of Child Health, College of Medicine, King Khalid University, Abha, Kingdom of Saudi Arabia.
- Alhada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia.
- Department of Pediatrics and Pediatric Hepatology, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
- Department of Medical Genetics, King Fahad Medical City, Riyadh, Saudi Arabia.
ORCID-Profile: Naglaa M Kamal
Zitieren
APA
Oshi, M. A. M., Alfaifi, J., Alqahtani, Y. A. M., Aljabri, M. F., Kamal, N. M., Althopaity, J., Althobaiti, K. A., Almalki, A. M., Abosabie, S. A. S., Abosabie, S. A., Sherbiny, H. S., Almanjoomi, S. K., & Abdallah, E. A. A. (2024). “Progressive myoclonic ataxia and developmental/epileptic encephalopathy associated with a novel homozygous mutation in TCN 2 gene”. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.2282
Vancouver
Oshi MAM, Alfaifi J, Alqahtani YAM, Aljabri MF, Kamal NM, Althopaity J, et al. “Progressive myoclonic ataxia and developmental/epileptic encephalopathy associated with a novel homozygous mutation in TCN 2 gene”. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.2282
BibTeX
@article{Oshi2024,
author = {Oshi, Mohammed Ahmed Mohammed and Alfaifi, Jaber and Alqahtani, Youssef Ali M and Aljabri, Mohammed Fahad and Kamal, Naglaa M and Althopaity, Jwaher and Althobaiti, Khalid A and Almalki, Abdullah M and Abosabie, Salma A S and Abosabie, Sara A and Sherbiny, Hanan Sakr and Almanjoomi, Saif K and Abdallah, Enas A A},
title = {“Progressive myoclonic ataxia and developmental/epileptic encephalopathy associated with a novel homozygous mutation in TCN 2 gene”},
journal = {Molecular Genetics & Genomic Medicine},
year = {2024},
doi = {10.1002/mgg3.2282}
}
EUVIMED